DIGILITI MONEY (NASDAQ: DGLT) and Lion Biotechnologies (NASDAQ:IOVA) are both small-cap business services companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk and analyst recommendations.
This is a summary of recent ratings and recommmendations for DIGILITI MONEY and Lion Biotechnologies, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
DIGILITI MONEY currently has a consensus price target of $6.00, indicating a potential upside of 473.39%. Lion Biotechnologies has a consensus price target of $14.86, indicating a potential upside of 103.52%. Given DIGILITI MONEY’s higher probable upside, analysts clearly believe DIGILITI MONEY is more favorable than Lion Biotechnologies.
This table compares DIGILITI MONEY and Lion Biotechnologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares DIGILITI MONEY and Lion Biotechnologies’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|DIGILITI MONEY||$9.03 million||1.14||-$6.89 million||N/A||N/A|
Lion Biotechnologies has higher revenue, but lower earnings than DIGILITI MONEY.
Insider & Institutional Ownership
6.2% of DIGILITI MONEY shares are held by institutional investors. Comparatively, 76.0% of Lion Biotechnologies shares are held by institutional investors. 50.9% of DIGILITI MONEY shares are held by company insiders. Comparatively, 13.2% of Lion Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
About DIGILITI MONEY
Digiliti Money Group, Inc., formerly Digiliti Money, Inc., is a technology solutions and services provider to the financial services industry. The Company’s solutions and services enable its clients, such as banks, credit unions and alternative financial services providers (AFS) to offer their customers remote deposit capture (RDC) and prepaid mobile money technologies and related services. It offers RDC products for businesses and consumers; mobile money management products for consumers, and training and support services for its financial services industry customers. The RDC products are offered to banks and credit unions in the United States, Canada and Latin America. Its mobile money management products are offered to traditional financial institutions (FIs), as well as AFS in the United States, Canada and Latin America. These FIs and AFS providers include banks, credit unions, prepaid card issuers, check cashers and payday lenders.
About Lion Biotechnologies
Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.
Receive News & Ratings for DIGILITI MONEY Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DIGILITI MONEY and related companies with MarketBeat.com's FREE daily email newsletter.